Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
F901318 is an antifungal agent with a novel mechanism of action and potent activity against Aspergillus spp. An understanding of the pharmacodynamics (PD) of F901318 is required for selection of effective regimens for study in phase II and III clinical trials. Neutropenic murine and rabbit models of invasive pulmonary aspergillosis were used. The primary PD endpoint was serum galactomannan. The relationships between drug exposure and the impacts of dose fractionation on galactomannan, survival, and histopathology were determined. The results were benchmarked against a clinically relevant exposure of posaconazole. In the murine model, administration of a total daily dose of 24 mg/kg of body weight produced consistently better responses with increasingly fractionated regimens. The ratio of the minimum total plasma concentration/MIC ( C min /MIC) was the PD index that best linked drug exposure with observed effect. An average C min (mg/liter) and C min /MIC of 0.3 and 9.1, respectively, resulted in antifungal effects equivalent to the effect of posaconazole at the upper boundary of its expected human exposures. This pattern was confirmed in a rabbit model, where C min and C min /MIC targets of 0.1 and 3.3, respectively, produced effects previously reported for expected human exposures of isavuconazole. These targets were independent of triazole susceptibility. The pattern of maximal effect evident with these drug exposure targets was also apparent when survival and histopathological clearance were used as study endpoints. F901318 exhibits time-dependent antifungal activity. The PD targets can now be used to select regimens for phase II and III clinical trials. IMPORTANCE Invasive fungal infections are common and often lethal. There are relatively few antifungal agents licensed for clinical use. Antifungal drug toxicity and the emergence of drug resistance make the treatment of these infections very challenging. F901318 is the first in a new class of antifungal agents called the orotomides. This class has a novel mechanism of action that involves the inhibition of the fungal enzyme dihydroorotate dehydrogenase. F901318 is being developed for clinical use. A deep understanding of the relationship between dosages, drug concentrations in the body, and the antifungal effect is fundamental to the identification of the regimens to administer to patients with invasive fungal infections. This study provides the necessary information to ensure that the right dose of F901318 is used the first time. Such an approach considerably reduces the risks in drug development programs and ensures that patients with few therapeutic options can receive potentially life-saving antifungal therapy at the earliest opportunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561 · cited 3×
“X is the amount of drug in a compartment, R(1) represents the i.”
BackgroundF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Self-citation
Cited by
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
du Pré, S., Beckmann, N., Almeida, M. C., Sibley, G. E. M., Law, D., Brand, A. C., Birch, M., Read, N. D., & Oliver, J. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00231-18 · Cited by 111
“effects of F901318 treatment seen in various animal models of fungal infection (2, 3, 30).”
BackgroundSelf-citationAlkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97
“08) of mice treated with a high dose of POSA (30 mg/kg BID), which resulted in exposures in mice that are approximately six times the clinically relevant dose (32).”
BackgroundDevelopment and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80
Self-citation
Metadata
- Authors
- Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., Kolamunnage-Dona, R., Schwartz, J., Kennedy, A., Law, D., Birch, M., & Rex, J. H.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2017-09-06
- Volume
- 8
- Issue
- 4
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- OpenAlex
- W2748240768
- Cited by
- 78
- References
- 3
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. https://app.cochat.ai/papers/10.1128/mbio.01157-17
- The paper
- Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., Kolamunnage-Dona, R., Schwartz, J., Kennedy, A., Law, D., Birch, M., & Rex, J. H. (2017). Pharmacodynamics of the Orotomides against Aspergillus fumigatus : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. mBio. https://doi.org/10.1128/mbio.01157-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.